Journal of Pediatrics & Child Care
Research Article
Use of Diuretics for Bronchopulmonary Dysplasia Increases Metabolic Bone Disease in Preterm Infants
Bhatia S1,2*, Abraham MJ1,3, Mehdi MQ1,4, Niebuhr B1 and Jain SK1
1Department of Neonatology, Department of Pediatrics, University
of Texas Medical Branch, Galveston, TX USA
2Division of Pediatric Cardiology, Department of Pediatrics,
Children’s Hospital of Michigan, Detroit, MI USA
3Department of Neurology, University of Texas Health Science
Center San Antonio Joe and Teresa Long School of Medicine, San
Antonio, TX USA
4Department of Pediatric Cardiology, University of Texas Southwestern Medical Center, Dallas, TX USA
4Department of Pediatric Cardiology, University of Texas Southwestern Medical Center, Dallas, TX USA
*Address for Correspondence: Snigdha Bhatia, Division of Pediatric Cardiology,
Department of Pediatrics, Children’s Hospital of Michigan, Detroit, MI, USA Email Id: snigdhabhatia@gmail.com;
Phone: 832-991-2172
Submission: 08 June 2023
Accepted: 26 July 2023
Published: 31 July 2023
Copyright: © 2023 Bhatia S, et al. This is an open access
article distributed under the Creative Commons Attr-ibution
License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is
properly cited.
Keywords: Metabolic bone disease; Prematurity; Bronchopulmonary
dysplasia
Abstract
Objective: Preterm infants (PI) are at increased risk of developing
metabolic bone disease (MBD).This study assessed the association of
diuretics for bronchopulmonary dysplasia (BPD) with MBD.
Study Design: This retrospective study included infants ≤30 weeks gestation and birth weight ≤1500 grams. Infants were divided into diuretic group and control group. Diuretic use was defined as hydrochlorothiazide and spironolactone for >7 days and MBD as PTH >100 mg/dL. Data was analyzed using SPSS and p <0.05 was considered significant.
Results: The study included 201 infants, with a mean gestational age 26.31 ± 1.73 weeks. There were 68 (33%) in the diuretic group vs. 133 (67%) in the control group. 41 vs. 24% (p<0.05) infants in the diuretics group who received diuretics for BPD also developed MBD. 80% vs. 20% (p<0.001) infants with BPD were treated with diuretics. Diuretics did not improve the respiratory status in these PI. We found infants given diuretics remained on ventilation for longer total number of days (p<0.001).
Conclusion: PI treated with diuretics for BPD are more likely to develop MBD without any significant improvement in respiratory status
Study Design: This retrospective study included infants ≤30 weeks gestation and birth weight ≤1500 grams. Infants were divided into diuretic group and control group. Diuretic use was defined as hydrochlorothiazide and spironolactone for >7 days and MBD as PTH >100 mg/dL. Data was analyzed using SPSS and p <0.05 was considered significant.
Results: The study included 201 infants, with a mean gestational age 26.31 ± 1.73 weeks. There were 68 (33%) in the diuretic group vs. 133 (67%) in the control group. 41 vs. 24% (p<0.05) infants in the diuretics group who received diuretics for BPD also developed MBD. 80% vs. 20% (p<0.001) infants with BPD were treated with diuretics. Diuretics did not improve the respiratory status in these PI. We found infants given diuretics remained on ventilation for longer total number of days (p<0.001).
Conclusion: PI treated with diuretics for BPD are more likely to develop MBD without any significant improvement in respiratory status